Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James E. Ray is active.

Publication


Featured researches published by James E. Ray.


Investigational New Drugs | 2005

Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.

Jian Liang; Richard E. Moore; Eric D. Moher; John E. Munroe; Rima S. Al-awar; David A. Hay; David L. Varie; Tony Y. Zhang; James Abraham Aikins; Michael J. Martinelli; Chuan Shih; James E. Ray; Lowell Lee Gibson; Vasu Vasudevan; Lisa Polin; Kathryn White; Juiwanna Kushner; Chiab Simpson; Susan Pugh; Thomas H. Corbett

SummaryCryptophycins-1 and 52 (epoxides) were discovered to have in-vitro and in-vivo antitumor activity in the early 1990s. The chlorohydrins of these, Cryptophycins-8 and 55 (also discovered in the early 1990s) were markedly more active, but could not be formulated as stable solutions. With no method to adequately stabilize the chlorohydrins at the time, Cryptophycin-52 (LY 355073) entered clinical trials, producing only marginal antitumor activity. Since that time, glycinate esters of the hydroxyl group of the chlorohydrins have been synthesized and found to provide stability. Three of the most active were compared herein. Cryptophycin-309 (C-309) is a glycinate ester of the chlorohydrin Cryptophycin-296. The glycinate derivative provided both chemical stability and improved aqueous solubility. After the examination of 81 different Cryptophycin analogs in tumor bearing animals, C-309 has emerged as superior to all others. The following %T/C and Log Kill (LK) values were obtained from a single course of IV treatment (Q2d × 5) against early staged SC transplantable tumors of mouse and human origin: Mam 17/Adr [a pgp (+) MDR tumor]: 0%T/C, 3.2 LK; Mam 16/C/Adr [a pgp (−) MDR tumor]: 0%T/C, 3.3 LK; Mam 16/C: 0%T/C, 3.8 LK; Colon 26: 0%T/C, 2.2 LK; Colon 51: 0%T/C, 2.4 LK; Pancreatic Ductal Adenocarcinoma 02 (Panc 02): 0%T/C, 2.4 LK; Human Colon HCT15 [a pgp (+) MDR tumor]: 0%T/C, 3.3 LK; Human Colon HCT116: 0%T/C, 4.1 LK. One additional analog, Cryptophycin-249 (C-249, the glycinate of Cryptophycin-8), also emerged with efficacy rivaling or superior to C-309. However, there was sufficient material for only a single C-249 trial in which a 4.0 LK was obtained against the multidrug resistant breast adenocarcinoma Mam-16/C/Adr. C-309 and C-249 are being considered as second-generation clinical candidates.


Tetrahedron Letters | 1993

Cleavage of chiral 4-phenyl-2-oxalidinones with TMSI: Application to the synthesis of carbacephems

Jack W. Fisher; James M. Dunigan; Lowell D. Hatfield; Richard Charles Hoying; James E. Ray; Kristina Lynn Thomas

Abstract A new technique for cleaving N-substituted 4-phenyl-2-oxazolidinones is described. Thus reaction of a 7-[4-phenyl-2-oxazolidinone]-carbacephem with TMSI and HMDS in acetonitrile, followed by DABCO, then aqueous hydrochloric acid gives the carbacephem nucleus, carbon dioxide, and acetophenone. This method allows a more versatile use of 4-phenyl-2-oxazolidinone as a chiral auxiliary and N-protective group in the synthesis of carbacephems.


Bioorganic & Medicinal Chemistry Letters | 1992

The synthesis of o-aminophenyl sulfate metabolites of the oncolytic sulfonylureas

John E. Toth; James E. Ray; William J. Ehihardt

Abstract Application of the Boyland-Sims oxidation to 4-chloro- and 3,4-dichloroaniline is reported.


Journal of Medicinal Chemistry | 1996

Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs

Bryan H. Norman; Chuan Shih; John E. Toth; James E. Ray; Jeffrey Alan Dodge; Doug W. Johnson; Pamela Rutherford; Richard M. Schultz; John F. Worzalla; Chris J. Vlahos


Archive | 1993

Antitumor compositions and methods of treatment

James E. Ray; John E. Toth; J. Jeffry Howbert


Journal of Medicinal Chemistry | 1997

Sulfonimidamide analogs of oncolytic sulfonylureas.

John E. Toth; Gerald B. Grindey; William J. Ehlhardt; James E. Ray; George B. Boder; Jesse R. Bewley; Kim K. Klingerman; Susan B. Gates; Sharon M. Rinzel; Richard M. Schultz; Leonard C. Weir; John F. Worzalla


Biochemistry | 2000

Structures of three inhibitor complexes provide insight into the reaction mechanism of the human methylenetetrahydrofolate dehydrogenase/cyclohydrolase.

Andrea Schmidt; Haiping Wu; Robert E. MacKenzie; Victor J. Chen; Jesse R. Bewly; James E. Ray; John E. Toth; Miroslaw Cygler


Journal of Medicinal Chemistry | 2003

A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.

Rima Al-awar; James E. Ray; Richard M. Schultz; Sherri L. Andis; Joseph H. Kennedy; Richard E. Moore; Jian Liang; Trimurtulu Golakoti; Gottumukkala V. Subbaraju; Thomas H. Corbett


Bioorganic & Medicinal Chemistry Letters | 2004

1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors

Rima S. Al-awar; James E. Ray; Kyle Andrew Hecker; Jianping Huang; Philip Parker Waid; Chuan Shih; Harold B. Brooks; Charles D. Spencer; Scott A. Watkins; Bharvin Patel; Nancy B. Stamm; Catherine A. Ogg; Richard M. Schultz; Eileen L. Considine; Margaret M. Faul; Kevin A. Sullivan; Stanley P. Kolis; John L. Grutsch; Sajan Joseph


Archive | 2000

Agents and methods for the treatment of proliferative diseases

Rima Al-awar; Kyle Andrew Hecker; James E. Ray; Jianping Huang; Sajan Joseph; Tiechao Li; Michael Paal; Radhakrishnan Rathnachalam; Chuan Shih; Philip Parker Waid; Xun Zhou; Guoxin Zhu

Collaboration


Dive into the James E. Ray's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rima Al-awar

Ontario Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge